By Louise Rasmussen, Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN (Reuters) - Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, said on Wednesday it will cut 9,000 jobs in a bid to reignite growth and fend off intense competition from U.S. rival Eli Lilly and a wave of compounded copycat drugs. The restructuring, including the largest layoff in Denmark's history, is expected to save 8 billion Danish crowns ($1.25 billion) annually and comes as Novo Nordisk is battling to revive its fo ...